<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2017-09-08" updated="2019-12-02">
  <drugbank-id primary="true">DB13900</drugbank-id>
  <name>Equine Botulinum Neurotoxin A Immune FAB2</name>
  <description>Equine Botulinum Neurotoxin A Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype A. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.</description>
  <cas-number/>
  <unii>LE3J6I6DXP</unii>
  <groups>
    <group>approved</group>
    <group>experimental</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Equine Botulinum Neurotoxin A Immune FAB2 is indicted for use in documented or suspected exposure to botulinum toxin serotype A in adults and pediatric patients [FDA Label].</indication>
  <pharmacodynamics>Equine Botulinum Neurotoxin A Immune FAB2 binds to botulinum toxin serotype A to prevent toxicity [FDA Label].</pharmacodynamics>
  <mechanism-of-action>Equine Botulinum Neurotoxin A Immune FAB2 is a mix of polyclonal antibodies for [DB00083] [FDA Label]. It binds to the toxin with high-affinity and prevents binding to ganglioside anchorage sites and membrane-bound receptors on cholinergic nerve terminals. This prevents internalization of the toxin into the cell and ultimately prevents it from exerting its toxic effects. Due to the long-lasting effects of botulinum toxin, the antibodies must be administered before symptoms present to prevent toxicity.</mechanism-of-action>
  <toxicity>Equine Botulinum Neurotoxin A Immune FAB2 may produce anapylaxis or anaphylactoid reactions particularly in patients who have previously been exposed to equine-derived antivenom or antitoxins or patient with prexisting hypersensitivity to horses, asthma, or hay fever [FDA Label]. Serum sickness reactions may present 10-21 days after infusion. Various infusion reactions may occur dependent on the rate of infusion. These include chills, fever, headaches, nausea, and vomiting. Arthralgia, myalgia, and vasovagal reactions may also occur independently of infusion rate. Because the antibodies are derived from equine plasma there is a risk of infectious disease transmission although this is controlled through manufacturing processes.&#13;
</toxicity>
  <metabolism>There is no metabolism data available. Equine Botulinum Neurotoxin A Immune FAB2 is assumed to be broken down similarly to other proteins and antibodies in systemic circulation.</metabolism>
  <absorption>Administration of one vial of containing at least 4500 Units produced a mean Cmax of 2.69 Units/mL. Administration of two vials produced a mean Cmax of 6.23 Units/mL [FDA Label].</absorption>
  <half-life>Equine Botulinum Neurotoxin A Immune FAB2 was observed to have a mean half life of 8.64 h after administration of one vial and 10.20 h after two vials [FDA Label].</half-life>
  <protein-binding>There is no protein binding data available.</protein-binding>
  <route-of-elimination>No data is available on excretion of Equine Botulinum Neurotoxin A Immune FAB2.</route-of-elimination>
  <volume-of-distribution>Equine Botulinum Neurotoxin A Immune FAB2 was found to have a mean Vd of 3.637 L after administration of one vial and 3.993 L after two vials [FDA Label].</volume-of-distribution>
  <clearance>Equine Botulinum Neurotoxin A Immune FAB2 was observed to have a mean clearance rate of 293 mL/h after administration of one vial and 285 mL/h after two.</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Botulinum Neurotoxin A immune FAB2 (equine)</synonym>
    <synonym language="english" coder="">BOTULINUM NEUROTOXIN A IMMUNE FAB2, EQUINE</synonym>
  </synonyms>
  <products>
    <product>
      <name>Bat</name>
      <labeller>Emergent BioSolutions Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60492-0075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA125462</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Bat</name>
      <ingredients>Equine Botulinum Neurotoxin A Immune FAB2 + Equine Botulinum Neurotoxin B Immune FAB2 + Equine Botulinum Neurotoxin C Immune FAB2 + Equine Botulinum Neurotoxin D Immune FAB2 + Equine Botulinum Neurotoxin E Immune FAB2 + Equine Botulinum Neurotoxin F Immune FAB2 + Equine Botulinum Neurotoxin G Immune FAB2</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB13900.pdf?1505424804</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911469</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004101</id>
      <name>Botulinum neurotoxin type A</name>
      <organism>Clostridium botulinum</organism>
      <actions>
        <action>antibody</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P10845" source="Swiss-Prot">
        <name>Botulinum neurotoxin type A</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Inhibits acetylcholine release. The botulinum toxin binds with high affinity to peripheral neuronal presynaptic membrane to the secretory vesicle protein SV2. It binds directly to the largest luminal loop of SV2A, SV2B and SV2C. It is then internalized by receptor-mediated endocytosis. The C-terminus of the heavy chain (H) is responsible for the adherence of the toxin to the cell surface while the N-terminus mediates transport of the light chain from the endocytic vesicle to the cytosol. After translocation, the light chain (L) hydrolyzes the 197-Gln-|-Arg-198 bond in SNAP-25, thereby blocking neurotransmitter release. Inhibition of acetylcholine release results in flaccid paralysis, with frequent heart or respiratory failure.</specific-function>
        <gene-name>botA</gene-name>
        <locus/>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions>627-647
656-676</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>149452.615</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="1491">Clostridium botulinum</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10845</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>BXA1_CLOBO</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.24.69</synonym>
          <synonym>atx</synonym>
          <synonym>bna</synonym>
          <synonym>BoNT/A</synonym>
          <synonym>Bontoxilysin-A</synonym>
          <synonym>BOTOX</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017329|Botulinum neurotoxin type A
MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN
PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG
STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY
GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN
RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA
KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV
LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT
GLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE
ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG
KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA
AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG
AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK
VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA
MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK
VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI
GSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN
EYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT
NNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN
EKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPR
GSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA
GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK
LVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF01742</identifier>
            <name>Peptidase_M27</name>
          </pfam>
          <pfam>
            <identifier>PF07951</identifier>
            <name>Toxin_R_bind_C</name>
          </pfam>
          <pfam>
            <identifier>PF07953</identifier>
            <name>Toxin_R_bind_N</name>
          </pfam>
          <pfam>
            <identifier>PF07952</identifier>
            <name>Toxin_trans</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>host cell presynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metalloendopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inhibition of neurotransmitter uptake</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pathogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>